Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025

The IASLC, Guardant Health, the Global Lung Cancer Coalition and AstraZeneca announced the Lung Ambition Alliance, a new partnership to eliminate lung cancer as a cause of death.

Read More »

Pfizer’s Avastin biosimilar wins FDA approval

The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche Holding AG’s blockbuster cancer treatment Avastin.

Read More »

Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

Read More »

Weekend Highlights from 2019 ASCO Annual Meeting

There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.

Read More »

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc. drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, sending the U.S. biotechnology company’s share up nearly 6 percent.

Read More »

Merck’s Keytruda sets new five-year survival standard for advanced lung cancer

Nearly a quarter of patients who received Merck & Co.’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting.

Read More »

AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.

Read More »

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.

Read More »

FDA approves Roche’s small cell lung cancer treatment

Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.

Read More »

Lilly combo therapy succeeds in lung cancer study

Eli Lilly and Co.’s combination cancer treatment met the main goal of a late-stage clinical trial in testing on patients with a form of lung cancer, the drugmaker announced.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom